Loading...
Axonics, Inc.
AXNX•NASDAQ
Healthcare
Medical - Devices
$70.98
$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $109.73M in Q4 2023 to $116.19M in Q3 2024. Gross profit continued to perform well, with margins at 77% in the latest quarter. Operating income reached -$6.27M in Q3 2024, holding a steady -5% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $421000.00. Net income dropped to -$21000.00, keeping EPS at -$0.00. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan